In 2023, Japan led the market for Global Systemic Hormonal Preparations Sales (excluding sex hormones and insulins) with a significant value of 42.97 million USD, reflecting a notable year-on-year growth rate of 12.9%. Germany, the second-largest market, showed a modest growth of 2.23% at 25.91 million USD. Canada and Spain followed, with their market shares demonstrating moderate increases of 4.27% and 0.22%, respectively. Costa Rica reported the highest year-on-year growth at 11.42%, although from a smaller base value. Several countries, including Greece and New Zealand, experienced negative growth, indicating market challenges.
Future trends to watch include:
- Potential market expansion in Japan, given its substantial growth rate.
- The evolving regulatory environment and healthcare policies in Europe, affecting countries like Germany and Spain.
- Opportunities for growth in emerging markets such as Costa Rica, driven by recent high growth rates.
- Technological advancements and new product developments aiming to reinvigorate sluggish markets like Greece and Hungary.
Top countries in Systemic Hormonal Preparations Sales (Excluding Sex Hormones and Insulins) Share by Country (Million US Dollars)
| # | 10 Countries | Percent | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Japan | 42.97 | 2023 | +1.62% | +12.9% | View data |
| 2 | 2 Germany | 25.91 | 2023 | +2.02% | +2.23% | View data |
| 3 | 3 Canada | 8.87 | 2023 | +1.99% | +4.27% | View data |
| 4 | 4 Spain | 7.76 | 2023 | +3.57% | +0.22% | View data |
| 5 | 5 Croatia | 2.47 | 2023 | +2.2% | +0.98% | View data |
| 6 | 6 Greece | 2.18 | 2023 | +0.85% | -3.53% | View data |
| 7 | 7 Sweden | 1.9 | 2023 | +4.19% | -1.84% | View data |
| 8 | 8 Czech Republic | 1.63 | 2023 | +2.73% | +1.16% | View data |
| 9 | 9 Switzerland | 1.58 | 2023 | +1.72% | +1.52% | View data |
| 10 | 10 Denmark | 1.22 | 2023 | -0.81% | -1.59% | View data |
